Altered apoptosis pathways in mantle cell lymphoma.

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma (NHL) with poor prognosis and resistance to therapy.
• The blastoid variant (MCL-BV) exhibits an even worse clinical outcome, with poorly understood neoplastic transformation mechanisms.
• Overexpression of BCL2, BCL-family proteins, and CD40, alongside decreased FAS expression, contributes to MCL pathogenesis and survival.

Purpose of the Study:

• To investigate the molecular mechanisms underlying neoplastic transformation in MCL and its relationship to MCL-BV.
• To identify altered cell signaling pathways and potential therapeutic targets in MCL.
• To explore the utility of gene expression analysis for predicting patient risk and treatment response.

Main Methods:

• Gene expression analysis using microarrays.
• Analysis of protein expression including BCL-family members, CD40, and FAS.
• Assessment of cell cycle regulators like cyclin D1, CDK2, CDK4, and RB1.

Main Results:

• MCL exhibits overexpression of BCL2, BCLX, and CD40, while BAX and BAK expression is not elevated.
• Pro-apoptotic FAS expression is decreased, favoring CD40-mediated cell survival.
• Overexpression of cyclin D1, CDK2, and CDK4 drives cell cycle progression through RB1 phosphorylation and E2F release.

Conclusions:

• Altered apoptotic and cell cycle pathways are key features of MCL pathogenesis.
• Gene expression profiling provides insights into MCL biology and can aid in risk stratification.
• Understanding these molecular alterations may lead to improved therapeutic strategies for MCL patients.